RECURSION PHARMACEUTICALS, INC. Financing Cash Flow
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Financing Cash Flow of -$4.74 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$1.27M, a 101.30% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$3.47M, a 108.56% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $132.01M, a 1140.77% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $251.34M, a 1426.79% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $521.53M, a 71.49% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $304.12M, a 117.02% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $140.13M, a 9.21% decline from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $154.34M, a 66.34% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$4.74M 10-Q · filed 2026-08-05 | $127.27M derived: sum of 3 quarters · filed 2026-08-05 | $378.61M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$3.47M 10-Q · filed 2026-05-06 | $128.54M derived: sum of 2 quarters · filed 2026-05-06 | $379.88M derived: sum of 3 quarters · filed 2026-05-06 | $477.54M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $132.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $383.35M derived: sum of 2 quarters · filed 2026-02-25 | $481.00M derived: sum of 3 quarters · filed 2026-08-05 | $521.53M 10-K · filed 2026-02-25 |
| 2025-09-30 | $251.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $349.00M derived: sum of 2 quarters · filed 2026-08-05 | $389.53M 10-Q · filed 2025-11-05 | $400.17M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $97.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $138.19M 10-Q · filed 2026-08-05 | $148.82M derived: sum of 3 quarters · filed 2026-08-05 | $165.29M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $40.53M 10-Q · filed 2026-05-06 | $51.17M derived: sum of 2 quarters · filed 2026-05-06 | $67.63M derived: sum of 3 quarters · filed 2026-05-06 | $330.75M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $10.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $27.10M derived: sum of 2 quarters · filed 2026-02-25 | $290.22M derived: sum of 3 quarters · filed 2026-02-25 | $304.12M 10-K · filed 2026-02-25 |
| 2024-09-30 | $16.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $279.58M derived: sum of 2 quarters · filed 2025-11-05 | $293.48M 10-Q · filed 2025-11-05 | $374.14M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $263.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $277.02M 10-Q · filed 2025-08-05 | $357.68M derived: sum of 3 quarters · filed 2026-02-25 | $411.44M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $13.90M 10-Q · filed 2025-05-05 | $94.56M derived: sum of 2 quarters · filed 2026-02-25 | $148.32M derived: sum of 3 quarters · filed 2026-02-25 | $152.11M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $80.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $134.42M derived: sum of 2 quarters · filed 2026-02-25 | $138.21M derived: sum of 3 quarters · filed 2026-02-25 | $140.13M 10-K · filed 2026-02-25 |
| 2023-09-30 | $53.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $57.55M derived: sum of 2 quarters · filed 2024-11-06 | $59.47M 10-Q · filed 2024-11-06 | $206.73M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $3.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.71M 10-Q · filed 2024-08-08 | $152.97M derived: sum of 3 quarters · filed 2025-02-28 | $155.30M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $1.92M 10-Q · filed 2024-05-09 | $149.18M derived: sum of 2 quarters · filed 2025-02-28 | $151.51M derived: sum of 3 quarters · filed 2025-02-28 | $154.18M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $147.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $149.59M derived: sum of 2 quarters · filed 2025-02-28 | $152.26M derived: sum of 3 quarters · filed 2025-02-28 | $154.34M 10-K · filed 2025-02-28 |
| 2022-09-30 | $2.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $5.00M derived: sum of 2 quarters · filed 2023-11-09 | $7.09M 10-Q · filed 2023-11-09 | $10.88M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $2.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $4.75M 10-Q · filed 2023-08-08 | $8.55M derived: sum of 3 quarters · filed 2024-02-29 | -$2.55M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $2.08M 10-Q · filed 2023-05-08 | $5.88M derived: sum of 2 quarters · filed 2024-02-29 | -$5.21M derived: sum of 3 quarters · filed 2024-02-29 | $458.49M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $3.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$7.30M derived: sum of 2 quarters · filed 2024-02-29 | $456.41M derived: sum of 3 quarters · filed 2024-02-29 | $458.54M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$11.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $452.61M derived: sum of 2 quarters · filed 2022-11-08 | $454.74M 10-Q · filed 2022-11-08 | $464.78M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $463.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $465.84M 10-Q · filed 2022-08-09 | $475.87M derived: sum of 3 quarters · filed 2023-02-27 | $705.60M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $2.13M 10-Q · filed 2022-05-10 | $12.17M derived: sum of 2 quarters · filed 2023-02-27 | $241.89M derived: sum of 3 quarters · filed 2023-02-27 | $242.27M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $10.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $239.76M derived: sum of 2 quarters · filed 2023-02-27 | $240.14M derived: sum of 3 quarters · filed 2023-02-27 | $246.13M 10-K · filed 2023-02-27 |
| 2020-09-30 | $229.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $230.10M derived: sum of 2 quarters · filed 2021-11-10 | $236.10M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $382.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $6.38M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $6.00M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $120.41M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |